DUBLIN–(BUSINESS WIRE)–The “Global Respiratory Disease Vaccine Market (2022-2027) by Infection, Type, Age Group, and Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Respiratory Disease Vaccine Market is estimated to be USD 22.16 Bn in 2022 and is expected to reach USD 29.71 Bn by 2027, growing at a CAGR of 6.04%.
Market Segmentations
The Global Respiratory Disease Vaccine Market is segmented based on Infection, Type, Age Group, and Geography.
By Infection, the market is classified into Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
By Type, the market is classified into Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
By Age Group, the market is classified into Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.
Countries Studied
America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Why buy this report?
The report offers a comprehensive evaluation of the Global Respiratory Disease Vaccine Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
The report also contains a competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.
Market Dynamics
Drivers
Increasing Prevalence of Respiratory Disorders
Clinical Trials and Vaccines Developments in Pipeline
Government Initiatives Supporting Respiratory Health
Restraints
Lack of Inadequate Delivery Infrastructure & Limited Awareness
Opportunities
Increasing R&D Expenditure by Leading Companies
Increase Vaccine Availability Through Reselling Collaborations
Challenges
Consumer Trust & Confidence in Respiratory Disease Vaccination
Report Highlights:
A complete analysis of the market, including the parent industry
Important market dynamics and trends
Market segmentation
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Respiratory Disease Vaccine Market, By Infection
7 Global Respiratory Disease Vaccine Market, By Type
8 Global Respiratory Disease Vaccine Market, By Age Group
9 Americas’ Respiratory Disease Vaccine Market
10 Europe’s Respiratory Disease Vaccine Market
11 Middle East and Africa’s Respiratory Disease Vaccine Market
12 APAC’s Respiratory Disease Vaccine Market
13 Competitive Landscape
14 Company Profiles
15 Appendix
Companies Mentioned
Abbott Laboratories
AstraZeneca PLC
Bayer Ag
BioDiem
BiondVax Pharmaceuticals Ltd.
Bristol-Myers Squibb Company
CanSino Biologics Inc.
Daiichi Sankyo Company, Ltd.
Emergent BioSolutions Inc.
Eurocept Group
Fluart Innovative Vaccines Kft.
Gamma Vaccines Pty. Ltd
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co., Inc.
Pfizer, Inc.
Sanofi SA
Seqirus GmbH
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Swedish Orphan Biovitrum AB
Mylan N.V.
Walvax Biotechnology Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/noh0xx
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
